Slingshot members are tracking this event:

FDA approves AstraZeneca's(AZN) Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
Tagrisso delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 18, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Tagrisso, Egfr Mutation, Non-small Cell Lung Cancer